Incyte (INCY) Misses Q4 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Incyte (INCY) Misses Q4 EPS by 7c

Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs

February 14, 2019 7:00 AM EST

Total product-related revenues of $468 million (+25%) in 4Q 2018 and $1.7 billion (+25%) for the full year 2018 Jakafi® (ruxolitinib) revenues of $380 million (+26%) in 4Q 2018 and $1.4 billion (+22%) for the full year 2018 Multiple late-stage product candidates provide additional opportunities to further accelerate revenue growth

Conference Call and Webcast Scheduled Today at 8:00 a.m. EST

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) today reports 2018 fourth quarter and year-end financial results, announces 2019 guidance and provides a... More